EKF Diagnostics Holdings ( (GB:EKF) ) has shared an announcement.
EKF Diagnostics Holdings plc announced that several members of its board have purchased a total of 550,000 ordinary shares at 22.0 pence per share. This move by the board members, including the Executive Chair, CEO, and CFO, indicates a strong vote of confidence in the company’s future prospects. The transaction, conducted on the London Stock Exchange’s AIM market, may positively impact the company’s market perception and stakeholder confidence.
More about EKF Diagnostics Holdings
EKF Diagnostics Holdings plc is a global diagnostics business listed on AIM, focusing on point-of-care analyzers in hematology and diabetes, central laboratory products, and life sciences services. The company specializes in manufacturing enzymes and custom products for diagnostic, pharmaceutical, and industrial applications. EKF operates five manufacturing sites across the US and Germany, selling products in over 120 countries worldwide.
YTD Price Performance: -13.89%
Average Trading Volume: 482,353
Technical Sentiment Signal: Strong Buy
Current Market Cap: £105.5M
Learn more about EKF stock on TipRanks’ Stock Analysis page.